Skip to content

Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders

Evaluation of the Effectiveness of a Web-based Treatment Program for Depression (Deprexis) for the Reduction of Depressive Symptoms in Patients With Multiple Sclerosis and Epilepsy. A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01663649
Enrollment
180
Registered
2012-08-13
Start date
2012-06-30
Completion date
2014-02-28
Last updated
2015-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, Online-Therapy, Deprexis, Self-help

Brief summary

200 persons (100 with multiple sclerosis and 100 with epilepsy) with depressive symptoms are recruited via the multiple sclerosis clinics of the University Medical Center Hamburg-Eppendorf and the epilepsy centre Alsterdorf and randomly assigned either to the online program deprexis or to a wait-list control condition. All participants receive free-of-charge online access to deprexis either immediately or with a six month delay. At three time points (1. prior to intervention, 2. after completion of the intervention nine weeks later and 3. at follow-up six month later), both groups are assessed via an anonymous online survey, which was implemented using the software package OPST®. The survey consists of different questionnaires. The Beck Depression Inventory (BDI) represents the primary outcome (IIT analysis for pre versus post). It is assumed that the severity of depressive symptoms will improve to a significantly greater extent in the deprexis than in the wait-list control condition in the course of nine weeks and will be maintained in a six month follow-up.

Detailed description

Deprexis is a web-based intervention that can be obtained online (www.deprexis.com). Deprexis encompasses 10 content modules with a strong focus on evidence-based cognitive-behavioral techniques, either from its so-called first (behavior-oriented), second (cognitive-oriented) or third wave (e.g. mindfulness and acceptance): (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving and (8) expressive writing and forgiveness, (9) positive psychology and (10) dreamwork and emotion-focus interventions. The ten modules are framed by one introductory and one summary module. Communication is carried out online via simulated dialogues. Patients have to respond to narrative text messages from the virtual therapists in multiple-choice response fashion, enabling them to express doubt, to affirm a particular message or to request more information. Text messages are aided with drawings, photographs and animations. The program is adaptive and selects exercises and contents on the basis of the subject's response. The modules are sequential and each module refers and builds upon previous one. Modules can (and should be) repeated within the intervention period.

Interventions

BEHAVIORALDeprexis

web-based treatment program for depression

BEHAVIORALWait-list

the wait-list group receives Deprexis after 6 month

Sponsors

Epilepsy Centre Alsterdorf
CollaboratorUNKNOWN
Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* presence of a confirmed diagnosis of multiple sclerosis or epilepsy * self-reported urge to be treated for depressive symptoms (no externally confirmed diagnosis necessary) * informed consent (provided online in line with regulations by the Hamburg Department of Data Security)

Exclusion criteria

* unable to provide informed consent * diagnosis of bipolar or schizophrenia spectrum disorders * substantial neurocognitive impairment (e.g. dementia) * acute suicidal tendencies as assessed with the Suicide Behaviors Questionnaire-Revised (SBQ-R). Subjects excluded for this reason are provided various emergency contacts and phone numbers.

Design outcomes

Primary

MeasureTime frameDescription
Severity of depressive symptoms7 DaysSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)

Secondary

MeasureTime frameDescription
quality of life14 daysquality of life as assessed by the WHO Quality of Life scale (WHO-QOL BREF)

Other

MeasureTime frameDescription
depressive symptoms7 daysdepressive symptoms as assessed by the Quick Inventory of Depressive Symptomatology (QIDS)
core self-evaluations7 dayscore self-evaluations as assessed by the Core Self-Evaluations Scale (CSES)
suicidal behaviors and tendencies7 dayssuicidal behaviors and tendencies as assessed by the Suicidal Behaviors Questionnaire-Revised (SBQ-R)
quality of life7 daysquality of life as assessed by the Hamburg MS Quality of Life Questionnaire (HALEMS)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026